Participants may not have had history of abdominal fistula or gastrointestinal perforation within the past  months
Gastrointestinal perforation or fistula in the  months prior to randomization unless underlying risk has been resolved (e.g., through surgical resection or repair)
History of abdominal fistula or gastrointestinal perforation within  months prior to day 
History of gastrointestinal perforation and/or fistulae within  months prior to initiation of study treatment;
History of known risks factors for bowel perforation
History of gastrointestinal perforation within last  months.
history of abdominal fistula or gastrointestinal perforation
History of gastrointestinal perforation and/or fistulae within  months prior to enrollment
No history of gastrointestinal fistula or gastrointestinal perforation <  days of registration
History of upper GI bleeding, ulceration or perforation within  months before the first dose of defactinib.
History of abdominal fistula or gastrointestinal perforation within  months prior to registration
At risk of bowel perforation
No myocardial infarction, gastrointestinal (GI) perforation/fistula, intraabdominal abscess, cerebrovascular accidents within six months prior to study entry
Prior history of gastrointestinal diverticulitis, perforation, or abscess.
History of prior gastrointestinal fistula and/or perforation
History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past  years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded
Any history of gastrointestinal (GI) perforation, history of intra-abdominal abscess within  months prior to starting treatment, or history of abdominal fistula unless the fistula history meets all the following: (a) the fistula was surgically repaired, (b) there has been no evidence of fistula for at least  months prior to starting treatment, (c) patient is deemed to be at low risk of recurrent fistula, and (d) the case must be discussed with the study PI
History of gastrointestinal fistula, hemorrhage, perforation or peptic ulcer disease
History of gastrointestinal perforation or fistula in the  months prior to study treatment, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)
Patients with active pharyngocutaneous fistula
Active fistula
The patient has a history of GI perforation and/or fistulae within  months prior to enrollment
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least  months, and patient is deemed to be at low risk of recurrent fistula
History of gastrointestinal perforation or fistula in the past  months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)
History of rectal fistula
History of abdominal fistula or gastrointestinal perforation =<  months prior to treatment with study drugs
History of abdominal fistula or gastrointestinal perforation =<  months prior to treatment with study drugs
History of abdominal fistula or gastrointestinal perforation within  months prior to day 
Patient is diagnosed with benign or malignant stricture, fistula, perforation, or leak
Gastrointestinal (GI) perforation/fistula
History of abdominal fistula or gastrointestinal perforation within  months prior to day  of FOLFIRI + bevacizumab initiation
History of abdominal fistula or gastrointestinal perforation within  months prior to randomization
History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within  months prior to randomization
Subjects with evidence of bladder perforation during diagnostic cystoscopy may be treated if perforation has resolved prior to dosing.
History of gastrointestinal perforation, abscess or fistula
Has a history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past  years; subjects with ulceration, bleeding or perforation in the lower bowel are not excluded
Patients with clinically significant gastrointestinal abnormalities including, but not limited to:\r\n* Clinically significant signs and/or symptoms of bowel obstruction within  months prior to starting treatment\r\n* History of intra-abdominal abscess within  months prior to starting treatment\r\n* History of gastrointestinal (GI) perforation within  months prior to starting treatment\r\n* Evidence of abdominal fistula within  months prior to starting treatment; history of abdominal fistula will be considered eligible if the fistula was surgically repaired, and there has been no evidence of fistula for at least  months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least  months, and patient is deemed to be at low risk of recurrent fistula
History of abdominal fistula or gastrointestinal perforation within  months prior to Day 
Patients at significant risk for GI perforation or fistula
The participant has a history of gastrointestinal perforation or fistula within  months.
History of abdominal fistula or gastrointestinal perforation at any point within  months prior to day  of study drug, unless surgically repaired
Patients may not have a prior history of GI perforation/fistula (within  months of first dose of protocol therapy) or risk factors of perforation
History of gastrointestinal perforation or fistula in the past  months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)
No history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past  years; patients with ulceration, bleeding or perforation in the lower bowel are NOT excluded
History of gastrointestinal perforation or fistula in the past  months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair)
have a history of GI perforation and/or fistulae within  months prior to enrollment
Have a history of gastrointestinal perforation and/or fistulae within  months prior to randomization.
Have a history of gastrointestinal perforation and/or fistulae within  months prior to randomization.
History of abdominal fistula or gastrointestinal perforation at any point within  months prior to day  of study drug, unless surgically repaired
Patients with a history of abdominal fistula or gastrointestinal (GI) perforation within  months prior to registration are not eligible
History of GI perforation. Patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired, there has been no evidence of fistula for at least  months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula
History of known risks factors for bowel perforation
Have a history of gastrointestinal perforation and/or fistula within  months prior to enrollment.
The participant has a history of gastrointestinal perforation or fistula within  months prior to randomization.
Participants may not have had history of abdominal fistula or gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula has healed or was surgically repaired, there has been no evidence of fistula for at least  months, and patient is deemed to be at low risk of recurrent fistula
History of gastrointestinal perforation =<  months prior to randomization
History of upper gastrointestinal bleeding, ulceration, or perforation within  months prior to the first dose of study drug
Prior history of bowel perforation
History of gastrointestinal (GI) perforation within  years or patient has a current or prior intestinal fistula
History of abdominal fistula or gastrointestinal perforation within  months prior to day 
History of abdominal fistula or gastrointestinal perforation within  months prior to day -
Ongoing bowel perforation or presence of bowel fistula or abscess within  months of registration
History of upper gastrointestinal bleeding, ulceration, or perforation within  months prior to the first dose of study drug.
History of upper gastrointestinal bleeding, ulceration, or perforation within  months prior to the first dose of protocol therapy
History of gastrointestinal perforation and/or fistulae within  months prior to course  day  (CD)
History of abdominal fistula or gastrointestinal perforation =<  months prior to treatment with study drugs
History of abdominal fistula or gastrointestinal perforation within  months prior to Day 
. History of upper GI bleeding, ulceration, or perforation within  months prior to the first dose of study drug.
History of upper gastrointestinal bleeding, ulceration, or perforation within  months.
Have a history of GI perforation and/or fistulae within  months prior to receiving study drugs.
History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past  years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded
History of abdominal fistula or gastrointestinal perforation
History of prior gastrointestinal perforation
History of complicated diverticulitis, including fistulae, abscess formation or gastrointestinal (GI) perforation
History of a gastrointestinal perforation
History of abdominal fistula or gastrointestinal perforation within  months prior to day 
Gastrointestinal perforation or fistulae within  months prior to randomization.
Patients with active gastrointestinal disorders, those requiring procedures that pre-dispose to gastrointestinal (GI) perforation, those with a history of transmural inflammatory conditions, and/or history of gastrointestinal ulcers, strictures, obstructions, fistulae, and/or abscess will be excluded from the study due to the risk of serious and sometimes fatal gastrointestinal perforation
Patients at risk for GI perforation.
History of gastrointestinal perforation or fistula in the past  months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved
